论文部分内容阅读
目的观察聚乙二醇干扰素α-2a联合利巴韦林治疗慢性丙型病毒性肝炎的效果及不良反应发生情况。方法 40例慢性丙型病毒性肝炎患者,随机分为观察组(21例)和对照组(19例)。观察组应用乙二醇干扰素α-2a联合利巴韦林进行治疗,对照组应用普通干扰素α-2a联合利巴韦林进行治疗,比较两组患者治疗24周、48周时的丙型肝炎病毒(HCV)DNA载量及阴转率、不良事件发生率。结果观察组24周与48周HCV DNA载量下降幅度超过3 lg(拷贝/ml)患者所占比例分别为71.4%、81.0%高于对照组的36.8%和47.4%,差异有统计学意义(P<0.05);24周与48周HCV DNA阴转率分别为66.7%和81.0%高于对照组的31.6%和42.1%,差异有统计学意义(P<0.05);观察组患者治疗及随访期间不良反应发生率为57.1%(12/21)高于对照组52.6%(10/19),差异无统计学意义(P>0.05)。结论慢性丙型病毒性肝炎应用聚乙二醇干扰素α-2a联合利巴韦林进行治疗具有较好效果,可持续有效抑制HCV病毒复制,安全性高,临床应用价值高。
Objective To observe the effect of peginterferon α-2a combined with ribavirin on chronic hepatitis C and the incidence of adverse reactions. Methods Forty patients with chronic hepatitis C were randomly divided into observation group (21 cases) and control group (19 cases). The observation group was treated with interferon alfa-2a and ribavirin, and the control group was treated with interferon alpha-2a combined with ribavirin. Compared with the control group at 24 weeks and 48 weeks, Hepatitis C virus (HCV) DNA load and negative conversion rate, incidence of adverse events. Results The percentage of HCV DNA load declining by more than 3 lg (copy / ml) in the observation group at 24 and 48 weeks was 71.4% and 81.0% respectively, which was significantly higher than that of the control group (36.8% and 47.4%, respectively) P <0.05). The HCV DNA negative conversion rates at 24 and 48 weeks were 66.7% and 81.0% respectively, which were significantly higher than those in control group (31.6% and 42.1%, P <0.05) The incidence of adverse reactions during the period was 57.1% (12/21) higher than that of the control group (52.6%, 10/19), with no significant difference (P> 0.05). Conclusion The treatment of chronic hepatitis C virus with pegylated interferon alfa-2a combined with ribavirin has a good effect and can effectively and effectively inhibit the replication of HCV virus. It has high safety and high clinical value.